Article

Verteporfin for injection

The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Related Content
Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib
January 21st 2025

Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Glaukos announces several positive clinical updates for its iDose platform
January 20th 2025

Glaukos announces several positive clinical updates for its iDose platform

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
January 19th 2025

InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company

Greek researchers report rare case of fungal endophthalmitis
January 18th 2025

Greek researchers report rare case of fungal endophthalmitis

© 2025 MJH Life Sciences

All rights reserved.